Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STALICLA Translates its Novel Precision Medicine Approach into Clinical Development with First Patient in Phase 1b Trial of STP1","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Signs Exclusive In-Licensing Agreement for Late-Stage Clinical Neuropsychiatric and Neurodevelopmental Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse (NIDA) To Cover Phase 3 Development Of Mavoglurant In Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Stalicla

    Menu

    Stalicla

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Stalicla

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

              Details:

              The proceeds will be utilized for the preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial evaluating STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).

              Lead Product(s): Ibudilast,Bumetanide

              Therapeutic Area: Neurology Product Name: STP1

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: SPRIM Global Investments

              Deal Size: $17.4 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stalicla

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

              Details:

              STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candidate for ASD-Phenotype 1.

              Lead Product(s): Ibudilast,Bumetanide

              Therapeutic Area: Neurology Product Name: STP1

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Firefly Neuroscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stalicla

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse (NIDA) To Cover Phase 3 Development Of Mavoglurant In Cocaine...

              Details:

              The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

              Lead Product(s): Mavoglurant

              Therapeutic Area: Psychiatry/Psychology Product Name: STP7

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute on Drug Abuse

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stalicla

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stalicla Signs Exclusive In-Licensing Agreement for Late-Stage Clinical Neuropsychiatric and Neurodevelopmental Disorder Treatment

              Details:

              Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist.

              Lead Product(s): Mavoglurant

              Therapeutic Area: Psychiatry/Psychology Product Name: AFQ056

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: $270.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stalicla

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder

              Details:

              In addition to showing good safety and tolerability profile, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystallized cognition composite.

              Lead Product(s): STP1

              Therapeutic Area: Psychiatry/Psychology Product Name: STP1

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Stalicla

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              STALICLA Translates its Novel Precision Medicine Approach into Clinical Development with First Patient in Phase 1b Trial of STP1

              Details:

              STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.

              Lead Product(s): STP1

              Therapeutic Area: Psychiatry/Psychology Product Name: STP1

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY